Blood cancer or hematologic cancer is one of the most prevalent forms of cancer worldwide, associated with a significant mortality rate affecting the production and function of blood cells, weakening immunity and oxygen transport. Each year, these cancers make up approximately 10% of all new cancer diagnoses and affect approximately 1.2 million people globally. Leukemia is a heterogeneous group of blood cancers affecting the bone marrow and blood, classified by lineage (lymphoid or myeloid) and progression rate (acute or chronic). Accurate genetic profiling is critical for diagnosis, prognosis, and therapy selection.
Genes2Me Leukemia NGS Panel offers comprehensive coverage of clinically relevant genes associated with major leukemia types:
The Panel delivers comprehensive genetic analysis for hereditary susceptibility to hematologic cancers. Because these cancers are highly heterogeneous, relying on phenotype alone often falls short. Our curated panel evaluates multiple clinically relevant genes in a single test, enabling efficient detection of overlapping genetic risks. This advanced NGS-based approach enables detection of SNVs, InDels, and fusion genes across key targets and supports accurate diagnosis, predicts prognosis, and informs treatment strategies such as chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. By leveraging high-throughput sequencing, clinicians can identify actionable variants, predict disease progression, and personalize therapy for improved outcomes.
It also facilitates early symptom detection, family planning, genetic counseling, and eligibility for clinical trials empowering precision care for patients and families. G2M offers end-to-end solutions for Leukemia detection by NGS that can accelerate and streamline the detection covering a range of blood cancer causing genes with assays based on hybridization capture target enrichment. Genes and variants selected as per AMP/ASCO/NCCN guidelines. The panel encompasses a list of 208 genes along with fusion and hotspots detection that can accelerate and streamline the analysis of these malignancies by combining recommended variants with the analytical capability of G2M’s Cliseq Interpreter Platform to support clinical decision making leading to personalized treatment strategies.
| Features | Performance |
|---|---|
| Coverage uniformity (0.2X) | >99% |
| Reproducibility (%) | 98 |
| Sensitivity (%) | 98.5 |
| On Target Ratio (%) | 75-85 |
| Parameter | Description |
| Commercial name and catalogue number: | Leukemia NGS Panel |
| Enrichment methodology: | Hybridization target capture |
| No. of genes covered: | 208 |
| Mutation types: | SNV/ InDels/ CNV/DNA & RNA Fusions |
| Covered region: | Whole CDS, DNA & RNA fusions, Hotspots |
| Target size: | 653 Kb |
| Coverage recommendations: | 1200X |
| Data requirement per sample: | 800 Mb |
| Sample type: | FFPE |
| Platform compatibility : | Illumina, Thermo Fisher (Ion Torrent), MGI, Element Biosciences |
| Data analysis platform: | G2M CliSeq Interpreter |
| Bioinformatics Support: | Primary Analysis: FASTQ to annotated VCF Secondary Analysis: CNVs, SNVs, InDel, Fusions Tertiary Analysis: Clinical interpretation |
| Sample input: | DNA:50-500 ng RNA:20-200 ng |
| Workflow time: | Library Prep. (∼4 hrs.) + Hyb. (∼8 hrs.) |
| Shelf life: | 12 months (in recommended storage conditions) |
| Automation option: | G2M EZY-Auto Prep |
Consistent Fold 80 Values Indicating Superior Coverage Uniformity:
Fold 80 values for blood samples ranged from 1.23–1.35, showing highly uniform coverage with minimal sequencing bias supporting accurate and dependable variant detection.
Reliable Coverage Metrics for Leukemic Genes:
Coverage patterns for key cancer genes (BRCA1, PTEN, MSH2, MSH6, RET) show strong consistency, with mean (solid) and median (dashed) values closely aligned. The consistent coverage demonstrates the workflow’s robustness and reliability, ensuring dependable performance for routine clinical testing across blood and diverse sample types.
Marked On-Target Alignment Among Different Cancer Patient Samples:
n-target capture efficiency across cancer patient samples. All samples achieved >79% on-target alignment, reflecting the panel’s optimized probe design, high hybridization specificity, and robust sequencing performance.
| Commercial Name | Cat No. | Pack Size | Platform |
|---|---|---|---|
| Hemat NGS Test Kit for Leukemia | G710017-1 | 24 T | Illumina |
| G710017-2 | 96 T | Illumina | |
| G710017-3 | 96 T – EZY | Illumina – EZY | |
| Hemat NGS Test Kit for Leukemia | G710017-4 | 24 T | MGI |
| G710017-5 | 96 T | MGI | |
| G710017-6 | 96 T – EZY | MGI – EZY | |
| Hemat NGS Test Kit for Leukemia | G710017-7 | 24 T | Aviti |
| G710017-8 | 96 T | Aviti | |
| G710017-9 | 96 T – EZY | Aviti – EZY | |
| Hemat NGS Test Kit for Leukemia | G710017-10 | 24 T | Thermo |
| G710017-11 | 96 T | Thermo | |
| G710017-12 | 96 T – EZY | Thermo – EZY |
Download useful documents and technical information of blood cancer Hemat NGS Panel.
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
All products listed in the catalogue are the products of Genes2Me Private Limited. Apart from that, all other product names, trademarks and logos wherever used in the catalogue are the property of their respective owners.
© 2025 Genes2me. All rights reserved.
